Overview

Effect of Pyridorin in Patients With Diabetic Nephropathy

Status:
Completed
Trial end date:
2003-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
BioStratum
Treatments:
Pyridoxamine